Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Sarepta Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$16.74M. For fiscal 2025 it was -$655.26M, down 356.2% from the year before. The highest annual figure on record is $255.81M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$655.26M | -356.2% |
| FY2024 | Dec 31, 2024 | $255.81M | – |
| FY2023 | Dec 31, 2023 | -$223.43M | – |
| FY2022 | Dec 31, 2022 | -$494.34M | – |
| FY2021 | Dec 31, 2021 | -$421.69M | – |
| FY2020 | Dec 31, 2020 | -$537.25M | – |
| FY2019 | Dec 31, 2019 | -$681.06M | – |
| FY2018 | Dec 31, 2018 | -$331.38M | – |
| FY2017 | Dec 31, 2017 | -$163.55M | – |
| FY2016 | Dec 31, 2016 | -$261.12M | – |
| FY2015 | Dec 31, 2015 | -$214.94M | – |
| FY2014 | Dec 31, 2014 | -$130.10M | – |
| FY2013 | Dec 31, 2013 | -$89.01M | – |
| FY2012 | Dec 31, 2012 | -$28.18M | – |
| FY2011 | Dec 31, 2011 | -$34.63M | – |
| FY2010 | Dec 31, 2010 | -$19.47M | – |
| FY2009 | Dec 31, 2009 | -$14.13M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.14M | – |
| Q2 FY2026 | Jun 30, 2026 | $23.70M | -81.3% |
| Q1 FY2026 | Mar 31, 2026 | $369.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$406.33M | -336.1% |
| Q3 FY2025 | Sep 30, 2025 | -$84.94M | -365.4% |
| Q2 FY2025 | Jun 30, 2025 | $126.42M | +1476.7% |
| Q1 FY2025 | Mar 31, 2025 | -$290.41M | -765.3% |
| Q4 FY2024 | Dec 31, 2024 | $172.14M | +378.2% |
| Q3 FY2024 | Sep 30, 2024 | $32.00M | – |
| Q2 FY2024 | Jun 30, 2024 | $8.02M | – |
| Q1 FY2024 | Mar 31, 2024 | $43.65M | – |
| Q4 FY2023 | Dec 31, 2023 | $36.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$122.73M | – |
| Q1 FY2023 | Mar 31, 2023 | -$126.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$96.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$120.65M | – |
| Q2 FY2022 | Jun 30, 2022 | -$201.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$76.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$95.67M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$159.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$142.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$163.43M | – |
| Q3 FY2020 | Sep 30, 2020 | -$130.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$131.88M | – |
| Q1 FY2020 | Mar 31, 2020 | -$111.50M | – |
| Q4 FY2019 | Dec 31, 2019 | -$223.57M | – |
| Q3 FY2019 | Sep 30, 2019 | -$116.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$269.13M | – |
| Q1 FY2019 | Mar 31, 2019 | -$71.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$135.84M | – |
| Q3 FY2018 | Sep 30, 2018 | -$66.51M | – |
| Q2 FY2018 | Jun 30, 2018 | -$100.55M | – |
| Q1 FY2018 | Mar 31, 2018 | -$28.49M | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.02M | – |
| Q3 FY2017 | Sep 30, 2017 | -$43.35M | – |
| Q2 FY2017 | Jun 30, 2017 | -$61.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$37.61M | – |
| Q4 FY2016 | Dec 31, 2016 | -$86.73M | – |
See a number that looks wrong?